PDCD1 and small cell lung carcinoma: Furthermore, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are commonly used to treat advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [20].